216 related articles for article (PubMed ID: 24607293)
21. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ
BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317
[TBL] [Abstract][Full Text] [Related]
22. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.
Henderson DC; Copeland PM; Daley TB; Borba CP; Cather C; Nguyen DD; Louie PM; Evins AE; Freudenreich O; Hayden D; Goff DC
Am J Psychiatry; 2005 May; 162(5):954-62. PubMed ID: 15863798
[TBL] [Abstract][Full Text] [Related]
23. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia.
Breier A; Berg PH; Thakore JH; Naber D; Gattaz WF; Cavazzoni P; Walker DJ; Roychowdhury SM; Kane JM
Am J Psychiatry; 2005 Oct; 162(10):1879-87. PubMed ID: 16199834
[TBL] [Abstract][Full Text] [Related]
24. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia.
Fleischhacker WW; McQuade RD; Marcus RN; Archibald D; Swanink R; Carson WH
Biol Psychiatry; 2009 Mar; 65(6):510-7. PubMed ID: 18986646
[TBL] [Abstract][Full Text] [Related]
25. Double-blind, randomized comparison of olanzapine versus fluphenazine in the long-term treatment of schizophrenia.
Dossenbach MR; Folnegovic-Smalc V; Hotujac L; Uglesic B; Tollefson GD; Grundy SL; Friedel P; Jakovljevic MM;
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):311-8. PubMed ID: 14751428
[TBL] [Abstract][Full Text] [Related]
26. Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study.
Poyurovsky M; Isaacs I; Fuchs C; Schneidman M; Faragian S; Weizman R; Weizman A
Am J Psychiatry; 2003 Feb; 160(2):297-302. PubMed ID: 12562576
[TBL] [Abstract][Full Text] [Related]
27. Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial.
Schreiner A; Niehaus D; Shuriquie NA; Aadamsoo K; Korcsog P; Salinas R; Theodoropoulou P; Fernández LG; Uçok A; Tessier C; Bergmans P; Hoeben D
J Clin Psychopharmacol; 2012 Aug; 32(4):449-57. PubMed ID: 22722501
[TBL] [Abstract][Full Text] [Related]
28. Saffron aqueous extract prevents metabolic syndrome in patients with schizophrenia on olanzapine treatment: a randomized triple blind placebo controlled study.
Fadai F; Mousavi B; Ashtari Z; Ali beigi N; Farhang S; Hashempour S; Shahhamzei N; Bathaie SZ
Pharmacopsychiatry; 2014 Jul; 47(4-5):156-61. PubMed ID: 24955550
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial.
Loebel A; Cucchiaro J; Sarma K; Xu L; Hsu C; Kalali AH; Pikalov A; Potkin SG
Schizophr Res; 2013 Apr; 145(1-3):101-9. PubMed ID: 23415311
[TBL] [Abstract][Full Text] [Related]
30. The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study.
Poyurovsky M; Tal V; Maayan R; Gil-Ad I; Fuchs C; Weizman A
Eur Neuropsychopharmacol; 2004 Aug; 14(4):332-6. PubMed ID: 15163444
[TBL] [Abstract][Full Text] [Related]
31. A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia.
Shen JH; Zhao Y; Rosenzweig-Lipson S; Popp D; Williams JB; Giller E; Detke MJ; Kane JM
J Psychiatr Res; 2014 Jun; 53():14-22. PubMed ID: 24613032
[TBL] [Abstract][Full Text] [Related]
32. A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse.
Beasley CM; Sutton VK; Hamilton SH; Walker DJ; Dossenbach M; Taylor CC; Alaka KJ; Bykowski D; Tollefson GD;
J Clin Psychopharmacol; 2003 Dec; 23(6):582-94. PubMed ID: 14624189
[TBL] [Abstract][Full Text] [Related]
33. A randomized controlled trial of olanzapine improving memory deficits in Han Chinese patients with first-episode schizophrenia.
Wang CH; Li Y; Yang J; Su LY; Geng YG; Li H; Wang JK; Mu JL
Schizophr Res; 2013 Mar; 144(1-3):129-35. PubMed ID: 23352776
[TBL] [Abstract][Full Text] [Related]
34. A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D₂ receptor antagonist in the treatment of acute exacerbation of schizophrenia.
Schmidt ME; Kent JM; Daly E; Janssens L; Van Osselaer N; Hüsken G; Anghelescu IG; Van Nueten L
Eur Neuropsychopharmacol; 2012 Oct; 22(10):721-33. PubMed ID: 22464973
[TBL] [Abstract][Full Text] [Related]
35. Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Psychotic Depression in Remission: The STOP-PD II Randomized Clinical Trial.
Flint AJ; Meyers BS; Rothschild AJ; Whyte EM; Alexopoulos GS; Rudorfer MV; Marino P; Banerjee S; Pollari CD; Wu Y; Voineskos AN; Mulsant BH;
JAMA; 2019 Aug; 322(7):622-631. PubMed ID: 31429896
[TBL] [Abstract][Full Text] [Related]
36. Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial.
Strous RD; Stryjer R; Maayan R; Gal G; Viglin D; Katz E; Eisner D; Weizman A
Psychoneuroendocrinology; 2007 Feb; 32(2):96-105. PubMed ID: 17208382
[TBL] [Abstract][Full Text] [Related]
37. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study.
Kane JM; D'Souza DC; Patkar AA; Youakim JM; Tiller JM; Yang R; Keefe RS
J Clin Psychiatry; 2010 Nov; 71(11):1475-81. PubMed ID: 20816042
[TBL] [Abstract][Full Text] [Related]
38. Effects of olanzapine long-acting injection on levels of functioning among acutely ill patients with schizophrenia.
Witte MM; Case MG; Schuh KJ; Ascher-Svanum H
Curr Med Res Opin; 2012 Mar; 28(3):315-23. PubMed ID: 22236137
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
40. Is Sitagliptin Effective for Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia Patients? A Double-blind Placebo-controlled Clinical Trial.
Moghimi Sarani E; Memari E; Anushiravani A; Mowla A
J Clin Psychopharmacol; 2020; 40(5):487-490. PubMed ID: 32701903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
